Prelude Therapeutics Incorporated
PRLDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. With a market capitalization of $334.5M, it sits in small-cap territory. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Market Cap
$334.5M
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
-4.47
EPS (TTM)
$-1.00
EPS (Fwd)
$-0.94
ROE
-95.3%
ROA
-39.7%
Cash
$81.6M
Total Debt
$17.7M
Free CF
-$17.9M
52W Change
421.7%
Annual Financials
Cash vs Debt
Prelude Therapeutics Incorporated holds $81.6M in cash against $17.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$17.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -95.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Prelude Therapeutics Incorporated and its sector.